Pfizer and its German partner, BioNTech, said the efficacy rate of the vaccine, known as BNT162b2, was consistent across all age and race demographics and based on a total case-cohort of 170. Interim results published last week indicated an efficacy rate of 90% from a cohort of around 94 patients.
Pfizer's news was paired with an announcement that the FDA has approved an at-home coronavirus test from Lucira, which is available by prescription.
"I think this is a possible real windfall; this along with Pfizer and Moderna could put an end to this thing," Cramer said.
Cramer also noted that the Lucira test could even let people test themselves before work. However, a primary physician would have to write a prescription in order to test themselves.